The effect of Oleoyl ethanolamide (OEA) supplementation on blood hematological parameters, lipid profile, biomarkers of oxidative stress and inflammatory parameters in the blood of patients with acute ischemic brain stroke

Effect of Oleoyl ethanolamide supplementation on hematologic parameters, lipid profile, inflammatory parameters and oxidative stress biomarkers in patients with acute ischemic stroke

40 patients Individually were divided into two groups by the simple randomization method and by the decimal number table and receiving Oleoyl ethanolamide supplementation. Clinical trial with control group, With parallel groups, Three blind strains, Accidental

40 patients referred to Sina Hospital of Hamadan (consecutively) diagnosed with a physician with acute ischemic stroke were randomly divided into two groups with Allocation Concealment. Blinding of all organs as patients know only by computer code. Therapeutic codes are revealed at the end of the study and it is unclear whether the placebo or supplement is taken because the placebo capsules will be made to look very similar to Oleoyl ethanolamide. . Patients receive written consent to participate in the study and to participate in the sampling. After intervention, blood sample is taken and examined.

Entry requirements: Willingness to cooperate Acute ischemic stroke Exclusion criteria: taking immunosuppressive drugs History of rheumatic and collagen and vascular diseases History of recent infections (within 2 to 3 months) Swallowing disorders that are unable to take medication Sensitivity to compounds No regular use of supplements Not willing to cooperate Diabetes kidney disease

The intervention group received a daily supplement of Oleoyl ethanolamide (200 mg) along with main meals for 2 months. The control group should also take a placebo capsule daily for 2 months.

Hematologic parameters, lipid profile, inflammatory parameters and oxidative stress biomarkers

This is an interventional study with a randomized controlled trial study design. In this study, 40 patients referred to Sina Hospital of Hamadan (consecutively) with diagnosis of acute ischemic stroke physician will be included in the study. In this study, patients were randomly divided into two groups of Oleoyl ethanolamide and placebo with Allocation Concealment by random number table and based on their group of supplements receive the relevant for two months. They will receive a computer code. The personal code of any participant in this course of treatment is not disclosed. Treatment codes are revealed at the end of the study after the database is closed.

Participants receive the relevant supplements for two months after obtaining written consent from the group in which they are located. They will receive a computer code. The personal code of any participant in this course of treatment is not disclosed. Treatment codes are revealed at the end of the study after the database is closed. Capsules and placebo are similar in appearance, so clinical caregivers, researchers, outcome assessors and data analysts and the Committee on Safety and Data Monitoring know patients only by code and do not know which patient received the supplement or placebo.